Avenzo Therapeutics completes merger with Rallybio

PUBT · 18h ago
Avenzo Therapeutics completes merger with Rallybio
  • Avenzo Therapeutics completed its merger with Rallybio on November 20, 2026, with the combined company operating under the Avenzo name.
  • Shares are expected to begin trading on the Nasdaq Capital Market on November 23 under the ticker AVZO.
  • A concurrent private placement raised approximately $215 million; proceeds and existing cash are expected to fund operations into late 2028.
  • Pre-merger Avenzo holders owned 56.6% of the combined company, private placement investors 40.6% and pre-merger Rallybio holders 2.8%.
  • A previously announced special cash distribution totaling $83.6 million, or $13.90 per share, is scheduled for payment on November 30.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261120707360) on November 20, 2026, and is solely responsible for the information contained therein.